Take our poll: How does Breast Cancer Awareness Month make you feel?
Donate to Breastcancer.org when you checkout at Walgreens in October. Learn more about our Walgreens collaboration.
Podcast: Verzenio Improves Overall Survival in HR+ HER2- Adv BC
moderators
Posts: 8,558
Verzenio Improves Overall Survival in Hormone Receptor-Positive, HER2-Negative, Advanced Stage Breast Cancer
Sep 28, 2022
Dr. Matthew Goetz explains the latest results from the MONARCH 3 study on Verzenio.
At the European Society for Medical Oncology Congress 2022, Dr. Matthew Goetz presented interim overall survival results from the MONARCH 3 study showing that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer.
Listen to the podcast to hear Dr. Goetz explain:
- how Verzenio works
- the purpose of the MONARCH 3 study
- the difference between progression-free and overall survival and why each is important
- Verzenio side effects
- what the results mean for people diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer
0
Categories
Join Us on Zoom: Upcoming virtual meetups. Read more...
Give your account some personality! Add a profile photo.